Document is current
Any future updates will be listed below
-
Authors
Lee, Yoojin
Gilbert, Jessica R.
Waldman, Laura R.
Zarate, Carlos A. Jr.
Ballard, Elizabeth D.
-
Funding
Funding for this research was provided by:
National Institute of Mental Health (ZIAMH002927)
National Institute of Mental Health
- License Information
-
More Information
Article History
Accepted: 2 June 2025
First Online: 25 June 2025
Declarations
:
: Dr. Zarate is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation; as a co-inventor on a patent for the use of (2R,6R)-hydroxynorketamine, (S)-dehydronorketamine, and other stereoisomeric dehydroxylated and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain; and as a co-inventor on a patent application for the use of (2R,6R)-hydroxynorketamine and (2S,6S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and posttraumatic stress disorder. He has assigned his patent rights to the U.S. government but will share a percentage of any royalties that may be received by the government. All other authors have no conflict of interest to disclose, financial or otherwise.
: Not applicable.
: Not applicable.
: Not applicable.
